The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death

Nature Medicine

Volumn 22, Issue 6, 2016, Pages 624-631

  Pozzi, Chiara ^a   Cuomo, Alessandro ^a   Spadoni, Ilaria ^a   Magni, Elena ^a   Silvola, Alessio ^a   Conte, Alexia ^b   Sigismund, Sara ^b   Ravenda, Paola Simona ^a   Bonaldi, Tiziana ^a   Zampino, Maria Giulia ^a   Cancelliere, Carlotta ^c   Di Fiore, Pier Paolo ^a,b,d   Bardelli, Alberto ^b,e   Penna, Giuseppe ^a   Rescigno, Maria ^a,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; B RAF KINASE; BAK1 PROTEIN; CALRETICULIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PANITUMUMAB; PROTEIN; PROTEIN BAX; PUMA PROTEIN; THAPSIGARGIN; TRAMETINIB; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; INDOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN P21; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL DEATH; CELL MEMBRANE; CELL PHAGOCYTOSIS; CELL SURFACE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DENDRITIC CELL; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HT 29 CELL LINE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RNA TRANSLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PHAGOCYTOSIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALRETICULIN; CAMPTOTHECIN; CELL DEATH; CELL LINE, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; INDOLES; LEUCOVORIN; MICE; PHAGOCYTOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); PYRIDONES; PYRIMIDINONES; SULFONAMIDES; UNFOLDED PROTEIN RESPONSE; X-BOX BINDING PROTEIN 1;

EID: 84965048105     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4078     Document Type: Article

References (40)

1. Fakih, M.G. et al. Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol 33, 1809-1824 (2015).
2. Peeters, M. & Price, T. Biologic therapies in the metastatic colorectal cancer treatment continuum-Applying current evidence to clinical practice. Cancer Treat. Rev. 38, 397-406 (2012).
3. Prenen, H. et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 15, 3184-3188 (2009).
4. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
5. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
6. Sorich, M.J. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-Analysis of randomized, controlled trials. Ann. Oncol. 26, 13-21 (2015).
7. Price, T.J. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-Type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 15, 569-579 (2014).
8. Arteaga, C.L. & Engelman, J.A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282-303 (2014).
9. Modest, D.P. et al. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: A pooled analysis of three trials. Oncology 83, 241-247 (2012).
10. Kishiki, T. et al. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. Oncol. Rep. 32, 57-64 (2014).
11. Galluzzi, L., Senovilla, L., Zitvogel, L. & Kroemer, G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215-233 (2012).
12. Zitvogel, L. et al. Immunogenic tumor cell death for optimal anticancer therapy: The calreticulin exposure pathway. Clin. Cancer Res. 16, 3100-3104 (2010).
13. Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3, e955691 (2014).
14. Vacchelli, E. et al. Trial watch: chemotherapy with immunogenic cell death inducers. OncoImmunology 3, e27878 (2014).
15. Di Nicolantonio, F. et al. Wild-Type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
16. Obeid, M. ERp57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J. Immunol. 181, 2533-2543 (2008).
17. Panaretakis, T. et al. Mechanisms of pre-Apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578-590 (2009).
18. Kato, H. & Nishitoh, H. Stress responses from the endoplasmic reticulum in cancer. Front. Oncol. 5, 93 (2015).
19. Wang, M. & Kaufman, R.J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14, 581-597 (2014).
20. Garrido, G. et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J. Immunol. 187, 4954-4966 (2011).
21. Licitra, L. et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur. J. Cancer 49, 1161-1168 (2013).
22. Karapetis, C.S. et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin. Cancer Res. 20, 744-753 (2014).
23. Sahin, I.H. et al. Rare though not mutually exclusive: A report of three cases of concomitant KRAS and BRAF mutation and a review of the literature. J. Cancer 4, 320-322 (2013).
24. Samowitz, W.S. et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl. Cancer Inst. 98, 1731-1738 (2006).
25. Tol, J., Nagtegaal, I.D. & Punt, C.J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98-99 (2009).
26. Van Cutsem, E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011-2019 (2011).
27. Bokemeyer, C. et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann. Oncol. 22, 1535-1546 (2011).
28. Bokemeyer, C. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-Type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48, 1466-1475 (2012).
29. Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-Analysis. Eur. J. Cancer 51, 587-594 (2015).
30. Lamba, S. et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 8, 1475-1483 (2014).
31. Sigismund, S. et al. Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J. 32, 2140-2157 (2013).
32. Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491 (2010).
33. Rimoldi, M. et al. Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. Blood 106, 2818-2826 (2005).
34. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J.V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 1, 2856-2860 (2006).
35. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896-1906 (2007).
36. Olsen, J.V. et al. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol. Cell. Proteomics 8, 2759-2769 (2009).
37. Cox, J. et al. Andromeda: A peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805 (2011).
38. Elias, J.E. & Gygi, S.P. Target-decoy search strategy for mass spectrometry-based proteomics. Methods Mol. Biol. 604, 55-71 (2010).
39. Tyanova, S., Mann, M. & Cox, J. MaxQuant for in-depth analysis of large SILAC datasets. Methods Mol. Biol. 1188, 351-364 (2014).
40. Eden, E., Navon, R., Steinfeld, I., Lipson, D. & Yakhini, Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10, 48 (2009).